Fig. 4. Myc promotes Bcl2 expression to inhibit chemosensitivity of WERI-RB-1/CDDP cells.

A The relationship between Myc and Bcl2 identified by hTFtarget. B Co-expression of Myc and Bcl2 explored by MEM analysis. C The positive correlation between Myc and Bcl2 certified by the analysis of microarray GSE28133. D Differential expression of Bcl2 in retinoblastoma determined by RT-qPCR. E Differential expression of Bcl2 in retinoblastoma determined by western blot analysis (*p < 0.05 vs. normal tissues). F The binding of Myc to the Bcl2 promoter binding detected by ChIP assay. G Bcl2 expression determined by RT-qPCR. H Bcl2 expression determined by western blot analysis. I Myc silencing and Bcl2 overexpression efficiency determined by RT-qPCR (*p < 0.05 vs. cells transfected with oe-NC or sh-NC). J Cell viability assessed by CCK8 assay. K IC₅₀ value determined by CCK8 assay. L Cell proliferation assessed by EdU assay. M Cell apoptosis assessed by flow cytometry. N Expression of PARP, Cleaved PARP, caspase 3, and Cleaved caspase 3 in cells after transfection determined by western blot analysis. *p < 0.05 vs. cells transfected with oe-NC; ^#p < 0.05 vs. cells co-transfected with oe-Bcl2 + sh-NC. ^*/#p < 0.05; ^**/##p < 0.01; ^***/###p < 0.001; ^****/####p < 0.0001. The experiment was independently repeated three times.